Company Of The Day: Johnson & Johnson

JNJ: Johnson & Johnson logo
Johnson & Johnson


Johnson & Johnson (NYSE:J&J) plans to split into two publically traded companies. The first company will hold the company’s prescription-drug and medical-device businesses. The second will hold the company’s consumer businesses.

So What?

Relevant Articles
  1. Should You Buy Johnson & Johnson Stock At $177?
  2. Here’s Why Centene Stock Is A Better Bet Compared To This Pharmaceuticals Bellwether
  3. This Semiconductor Chip Company Is Likely To Offer Better Returns Over Johnson & Johnson Stock
  4. Does Johnson & Johnson Stock Have More Upside?
  5. Company Of The Day: Johnson & Johnson
  6. Here’s Why Humira Maker Is A Better Bet Compared To Johnson & Johnson Stock

While J&J’s consumer business is very high profile, it lags the pharma business in terms of growth and profitability. With the planned split, J&J could potentially unlock some value for shareholders.

See Our Complete Analysis For Johnson & Johnson

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates